ABVC Biopharma Inc logo

ABVC Biopharma Inc(ABVC)

upturn advisory logo
ADVISORIES YOU CAN VERIFY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.16
09/18/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close

Advisory Performance History (Simulated)Advisory Performance History info

Upturn Advisory & Investor View for ABVC

09/18/2026: ABVC (1-star) is currently NOT-A-BUY. Pass it for now.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit 119.12%
Avg. Invested days 37
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 09/18/2026

Upturn Scorecard

Upturn Star Rating

ABVC receives a 2-star rating, supported by available scored pillars. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

ABVC has moderate overall fundamentals (3 stars), with soft financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, strong revenue growth (+56.2%) is partially offset by negative earnings growth (-61.3%), soft cash generation (FCF margin -375.2%), soft profitability (net margin -993.6%).

Financial Health Rating

ABVC's financial health is supported by soft profitability, including gross margin of 100.0% and operating margin of -898.5%. Overall financial-health metrics support a 2-star score.

Growth Momentum Score

Revenue growth is ABVC's strongest growth driver at +56.2% FY2025 versus FY2024 (strong, 5 stars). By comparison, while earnings growth (-61.3%, negative) and free-cash-flow growth (-65.1%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

Institutional ownership is 4.1% and approximately 79.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 18.11% supports management-shareholder alignment.

Top 5 Institutional Investors

Geode Capital Management, LLC 0.83%
Vanguard Capital Management, LLC 0.72%
Vanguard Fiduciary Trust Co 0.37%
Renaissance Technologies Corp 0.36%
State Street Corp 0.27%

Unit Economics (Per $1K Revenue)

ABVC generates approximately $1,000 of gross profit, $-8,985 of operating income, and $-3,752 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong cash conversion and healthy margins support the rating, although capital efficiency remains below the highest tier.

Economic Dimensions

Effective Tax Rate: 5.32%

Quantitative Style Profile

ABVC has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 30.92M USD
Price to earnings Ratio -
1Y Target Price 2.02
Price to earnings Ratio -
1Y Target Price 2.02
Volume (30-day avg) 130.0K shares
Beta 0.61
52 Weeks Range 0.71 - 3.40
Updated Date 09/19/2026
52 Weeks Range 0.71 - 3.40
Updated Date 09/19/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.29
Advertisement

Valuation

Trailing PE -
Forward PE -
Enterprise Value 33.42M
Price to Sales(TTM) 111.69
Enterprise Value 33.42M
Price to Sales(TTM) 111.69
Enterprise Value to Revenue 184.61
Enterprise Value to EBITDA -1.9
Shares Outstanding 26.65M
Shares Floating 21.10M
Shares Outstanding 26.65M
Shares Floating 21.10M
Percent Insiders 18.11
Percent Institutions 4.09

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

About ABVC Biopharma Inc

Exchange NASDAQ
Headquarters Fremont, CA, United States
IPO Launch date 2017-10-11
CEO & Interim CFO Dr. Uttam Yashwant Patil Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 16
Full time employees 16

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.